🎉 M&A multiples are live!
Check it out!

Denali Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Denali Therapeutics and other public comps.

See Denali Therapeutics Valuation Multiples

Denali Therapeutics Overview

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.


Founded

2013

HQ

United States of America
Employees

445

Financials

LTM Revenue $13.0M

LTM EBITDA -$477M

EV

$2.4B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Denali Therapeutics Financials

Denali Therapeutics has a last 12-month revenue of $13.0M and a last 12-month EBITDA of -$477M.

In the most recent fiscal year, Denali Therapeutics achieved revenue of $331M and an EBITDA of -$180M.

Denali Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Denali Therapeutics valuation multiples based on analyst estimates

Denali Therapeutics P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $108M $331M $9.3M $13.0M XXX
Gross Profit n/a n/a n/a XXX XXX
Gross Margin NaN% NaN% NaN% XXX XXX
EBITDA -$330M -$180M -$472M -$477M XXX
EBITDA Margin -305% -54% -5068% -3676% XXX
Net Profit -$291M -$326M -$145M XXX XXX
Net Margin -268% -99% -1559% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Denali Therapeutics Stock Performance

As of February 10, 2025, Denali Therapeutics's stock price is $22.

Denali Therapeutics has current market cap of $3.2B, and EV of $2.4B.

See Denali Therapeutics trading valuation data

Denali Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.4B $3.2B XXX XXX XXX XXX $-2.81

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Denali Therapeutics Valuation Multiples

As of February 10, 2025, Denali Therapeutics has market cap of $3.2B and EV of $2.4B.

Denali Therapeutics's trades at 186.4x LTM EV/Revenue multiple, and -5.1x LTM EBITDA.

Analysts estimate Denali Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Denali Therapeutics and 10K+ public comps

Denali Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.4B XXX XXX XXX
EV/Revenue 259.7x XXX XXX XXX
EV/EBITDA -5.1x XXX XXX XXX
P/E -7.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -4.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Denali Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Denali Therapeutics Valuation Multiples

Denali Therapeutics's NTM/LTM revenue growth is 353%

Denali Therapeutics's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Denali Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Denali Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Denali Therapeutics and other 10K+ public comps

Denali Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -97% XXX XXX XXX XXX
EBITDA Margin -5068% XXX XXX XXX XXX
EBITDA Growth 162% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -4715% XXX XXX XXX XXX
Revenue per Employee $0.7M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 31% XXX XXX XXX XXX
R&D Expenses to Revenue 128% XXX XXX XXX XXX
Opex to Revenue 160% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Denali Therapeutics Public Comps

See valuation multiples for Denali Therapeutics public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Denali Therapeutics M&A and Investment Activity

Denali Therapeutics acquired  XXX companies to date.

Last acquisition by Denali Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Denali Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Denali Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Denali Therapeutics

When was Denali Therapeutics founded? Denali Therapeutics was founded in 2013.
Where is Denali Therapeutics headquartered? Denali Therapeutics is headquartered in United States of America.
How many employees does Denali Therapeutics have? As of today, Denali Therapeutics has 445 employees.
Who is the CEO of Denali Therapeutics? Denali Therapeutics's CEO is Dr. Ryan J. Watts, PhD.
Is Denali Therapeutics publicy listed? Yes, Denali Therapeutics is a public company listed on NAS.
What is the stock symbol of Denali Therapeutics? Denali Therapeutics trades under DNLI ticker.
When did Denali Therapeutics go public? Denali Therapeutics went public in 2017.
Who are competitors of Denali Therapeutics? Similar companies to Denali Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Denali Therapeutics? Denali Therapeutics's current market cap is $3.2B
What is the current revenue of Denali Therapeutics? Denali Therapeutics's last 12-month revenue is $13.0M.
What is the current EBITDA of Denali Therapeutics? Denali Therapeutics's last 12-month EBITDA is -$477M.
What is the current EV/Revenue multiple of Denali Therapeutics? Current revenue multiple of Denali Therapeutics is 186.4x.
What is the current EV/EBITDA multiple of Denali Therapeutics? Current EBITDA multiple of Denali Therapeutics is -5.1x.
What is the current revenue growth of Denali Therapeutics? Denali Therapeutics revenue growth between 2023 and 2024 was -97%.
Is Denali Therapeutics profitable? Yes, Denali Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.